Who is sponsoring NCT01117636?

NCT01117636 is sponsored by Bayer.

What drugs are being tested in NCT01117636?

Interventions in NCT01117636: Acetylsalicylic acid (Fast release Aspirin, BAY1019036), Acetylsalicylic Acid (Aspirin, BAYE4465), Placebo.

What condition does NCT01117636 study?

NCT01117636 studies Drugs, Investigational.

Is NCT01117636 still recruiting?

NCT01117636 is currently completed. Last updated 19 December 2018.

Last reviewed 2018-12-19 · How we verify

NCT01117636: TAROT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate Analgesic Efficacy of Fast Release Aspirin

Completed Phase 3 Last updated 19 December 2018

What this trial tests

Phase 3 trial testing Acetylsalicylic acid (Fast release Aspirin, BAY1019036) in Drugs, Investigational in 514 participants. Completed in 7 July 2010.

Timeline

28 April 2010

Primary endpoint
7 July 2010

7 July 2010

Quick facts

Lead sponsor	Bayer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	514
Start date	28 April 2010
Primary completion	7 July 2010
Estimated completion	7 July 2010
Sites	2 locations across United States

Drugs / interventions tested

Acetylsalicylic acid (Fast release Aspirin, BAY1019036) — full drug profile →
Acetylsalicylic Acid (Aspirin, BAYE4465) — full drug profile →
Placebo

Conditions studied

Drugs, Investigational — all drugs for Drugs, Investigational →

Sponsor

Bayer — full company profile →

Who can join

Adults 16 to 45, any sex, with Drugs, Investigational. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to evaluate the analgesic efficacy of a single, oral dose of fast release aspirin tablets, 1000 mg (2 x 500 mg) compared to regular aspirin tablets, 1000 mg (2 x 500 mg) and placebo in subjects with postsurgical dental pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01117636 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 19 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01117636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing